Table 4 Multivariable analysis of factors influencing overall and disease-specific survival in validation set (n=84)

From: High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome

Variable

HR

95% CI

P-value

Overall survival

 Age (per year increase)

1.009

0.986–1.032

0.47

 AML (vs MDS/CMML)

4.861

2.537–9.314

<0.0001

 High-risk karyotypea

1.783

0.767–4.144

0.18

 Treatment with stem cell transplant

0.413

0.184–0.929

0.03

 p53 immunohistochemistry positivity (≥1% 3+ cells)

3.156

1.502–6.628

0.002

Disease-specific survival

 Age (per year increase)

1.013

0.994–1.033

0.18

 AML (vs MDS/CMML)

2.736

1.601–4.677

<0.0001

 High-risk karyotypea

1.408

0.737–2.687

0.30

 Treatment with stem cell transplant

0.465

0.254–0.852

0.01

 p53 immunohistochemistry positivity (≥1% 3+ cells)

2.467

1.364–4.461

0.003

  1. AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndrome.
  2. aDefined as Revised International Prognostic Scoring System high or very high risk for MDS/CMML cases and United Kingdom Medical Research Council adverse risk for AML cases.
Back to article page